Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14.5 to $15.
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14.5 to $15.